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 ABSTRACT 
 Two therapeutic programs were com-
pared in heifers at high risk for bovine 
respiratory disease (BRD) during a 208-
d feeding period. Program 1 [metaphylac-
tic tulathromycin followed by as-needed 
use of ceftiofur crystalline free acid, 
after a 14-d postmetaphylactic interval 
(PMI; treatment moratorium); T01] was 
compared with program 2 [metaphylactic 
tilmicosin phosphate followed by as-need-
ed use of enrofloxacin, after a 3-d PMI 
(treatment moratorium); T02]. Auction-
sourced heifers (n = 1,236; initial BW 
= 258 ± 2.1 kg) were randomized to 
treatment [T01, n = 620; T02, n = 616; 
8 pens/treatment] and processed. Rates 
of BRD (10.3 vs. 26.0%; P = 0.0001), 
BRD re-treatment (1.6 vs. 6.3%; P = 
0.0001), and G:F [0.27 vs. 0.24, deads 
in (P = 0.004); 0.28 vs. 0.27, deads out 
(P = 0.099)] were improved during the 
initial 70 d for T01 versus T02 heifers, 
respectively, but not during d 71 to 208. 
Medicine costs ($2.56 vs. $7.90/heifer; 
P < 0.0001), cost of gain (deads-in ba-
sis: $2.07 vs. $2.16/kg; P = 0.086), and 
profitability ($21.43 vs. −$2.55/heifer; P 
= 0.0935) were significantly improved for 
T01 versus T02 heifers, respectively. For 
high-risk cattle, a therapeutic program 
consisting of metaphylactic treatment 
with tulathromycin followed by use of 
ceftiofur crystalline free acid as a stan-
dard feedlot therapy, after a 14-d PMI, 
compared with a second program consist-
ing of metaphylactic tilmicosin phosphate 
followed by enrofloxacin, after a 3-d 
PMI, significantly reduced the incidences 
of both initial and re-treated BRD, 
thereby improving G:F, medicine costs, 
cost of gain (deads in), and profitability. 
 Key words:   bovine respiratory 
disease ,  ceftiofur crystalline free acid , 
 feedlot ,  tilmicosin ,  tulathromycin 
 INTRODUCTION 
 In the United States during 2010, 
25.6% of total cattle death loss was 
due to bovine respiratory disease 
(BRD), representing a $4.28 bil-
lion loss to the cattle industry, with 
overall treatment costs estimated to 
be $92.00 per animal (McNeill et al., 
1996; USDA, 2011). Metaphylaxis, or 
mass antimicrobial treatment upon 
animal arrival, is commonly used to 
reduce incidence of BRD (Taylor et 
al., 2010). Multiple studies have re-
ported favorable outcomes in high-risk 
cattle when antibiotic therapies are 
used metaphylactically. These thera-
pies, however, are not absolutely effec-
tive (Kilgore et al., 2005; Robb et al., 
2007; Washburn et al., 2009). Regard-
less, metaphylaxis can be beneficial 
compared with symptomatic treat-
ment (Johnson et al., 2008). Data are 
limited or equivocal regarding overall 
health, performance, and economic 
outcomes of cattle dosed metaphy-
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lactically (Van Donkersgoed et al., 
2008). Therapeutic programs, such 
as sequential use of antibiotics using 
extended postmetaphylactic intervals 
(PMI) and posttreatment intervals 
(PTI), with or without home pen 
recovery, could reduce the incidence of 
BRD and potentially improve profit-
ability. Previous studies with PMI 
have demonstrated differing results 
(Step et al., 2007; Van Donkersgoed 
et al., 2008).
In this experiment, 2 antimicrobi-
als, with different pharmacokinetics, 
were used metaphylactically in calves 
at high risk for developing BRD fol-
lowed by re-treatment with standard 
feedlot therapies (SFLT) after a PMI, 
as needed. Program 1 consisted of 
metaphylaxis upon arrival of tulath-
romycin (Draxxin Injectable Solution; 
Pfizer Animal Health, New York, 
NY). Fourteen days later, ceftiofur 
crystalline free acid (CCFA, Excede 
Sterile Suspension, Pfizer Animal 
Health) was used as an SFLT. Pro-
gram 2 consisted of metaphylaxis 
upon arrival of tilmicosin phosphate 
(Micotil 300 Injection; Elanco Animal 
Health, Indianapolis, IN). Three days 
later, enrofloxacin (Baytril Inject-
able Solution, Bayer Healthcare LLC, 
Animal Health Division, Shawnee 
Mission, KS) was used as an SFLT. 
Bactericidal activity has been re-
ported for tulathromycin (14 d; Cox 
et al., 2010), CCFA (7 d; Washburn 
et al., 2009), tilmicosin (3 d; Modric, 
1997), and for enrofloxacin (4 d; Robb 
et al., 2007). Our hypothesis was that 
a therapeutic program could provide a 
significant reduction in the incidence 
of BRD and positively affect produc-
tion parameters and overall profit-
ability.
MATERIALS AND METHODS
Experimental Design
This experiment was a random-
ized complete block design with pen 
as the experimental unit. Each block 
consisted of 2 adjacent pens with a 
total of 8 blocks. Blocking factors 
included arrival date and procurement 
source. Heifers within an arrival day 
and procurement source were as-
signed randomly, with no more than 
8 heifers assigned at a time, to 1 of 
2 pens in each block. Within blocks, 
pens were assigned randomly to treat-
ments. Heifers within a block were 
fed for the same number of days to 
achieve an acceptable slaughter BW. 
Treatment groups were tulathromycin 
(Draxxin) administered as a course 
of metaphylaxis on arrival followed 
by CCFA (Excede) if necessary after 
a 14-d PMI (T01, n = 620) for BRD 
therapy upon initial clinical presenta-
tion or tilmicosin phosphate (Micotil) 
as metaphylaxis on arrival followed 
by enrofloxacin (Baytril), if neces-
sary, after a 3-d PMI for initial BRD 
therapy (T02; n = 616; Table 1). 
Pens within each treatment were fed 
the same diet.
Animals
Heifers (n = 1,236; average BW = 
258 ± 2.1 kg) sourced from livestock 
auctions in Kentucky, Missouri, Okla-
homa, and Texas were transported by 
truck and assembled at a commercial 
feedlot in Watonga, Oklahoma, during 
a 2-wk period (18 November 2009 to 2 
December 2009) late in 2009. During 
this time, heifers remained segregated 
by day of arrival and source until a 
sufficient number arrived to allow a 
block to be placed. Heifers within an 
arrival day and source were randomly 
assigned to 1 of the 2 pens in each 
block before initial processing. Adja-
cent pens were of unlike treatments. 
Heifers were sorted (no more than 8 
heifers at a time) into pens within 
a block using a randomly generated 
sort. Vaccination status for viral or 
clostridial disease did not affect the 
inclusion–exclusion of heifers. Exclu-
sion criteria included systemic disease 
or physical conditions that might in-
terfere with the evaluation of BRD or 
the evaluation of the response to BRD 
therapy or prevent completion of the 
experiment duration (e.g., lameness, 
musculoskeletal abnormalities); known 
history of BRD, recent BRD therapy, 
or severe clinical signs of BRD on 
arrival; known or suspected vaccina-
tion within the previous 30 d against 
Mannheimia haemolytica or Pasteurel-
la multocida or both; and heifers that 
were moribund.
Following treatment assignments (d 
0), heifers were weighed and process-
ing began. Each heifer was vaccinated 
for viral infectious bovine rhinotrache-
itis, bovine viral diarrhea (types 1 and 
2), parainfluenza type 3, bovine re-
spiratory syncytial virus (Bovi-Shield 
Gold 5, Pfizer Animal Health), and 
clostridial (Ultra-Choice 7, Pfizer Ani-
mal Health) diseases and treated for 
parasites with doramectin (Dectomax 
Injectable Solution, Pfizer Animal 
Health) and albendazole (Valbazen 
Suspension, Pfizer Animal Health). 
Each heifer was implanted in the right 
ear with estradiol (8 mg) and tren-
bolone acetate (80 mg; Revalor-IH, 
Intervet Schering-Plough Inc., White-
house Station, NJ). All products were 
used according to label dosage and 
route of administration. A visual tag 
containing lot number and an individ-
ual identification number was placed 
in the left ear of each heifer along 
with an electronic identification tag, 
providing dual identification.
At an average of d 71 of the experi-
ment, heifers were removed from their 
pen no sooner than 30 min following 
morning feed delivery. Time of feed 
access was constant for both pens 
within a block and was allowed to 
prevent metabolic disturbances follow-
ing processing. Heifers were walked 
to the processing area where an 
implant containing 200 mg of trenbo-
lone (Finaplix-H; Intervet Schering-
Plough) was administered into the 
left ear of each heifer. Each heifer was 
also weighed individually. Heifers were 
housed outside in dirt-floored pens 
with a stocking density for each heifer 
of 20 m2 of pen space, 27.4 cm of 
linear feed bunk space, and 8.6 cm of 
linear water tank space. The experi-
ment was conducted from November 
2009 to June 2010.
Heifers were cared for in a humane 
manner at all times with regard to 
well-being, consistent with experimen-
tal-site operating procedures. Heifers 
were observed at least once daily to 
ensure the animals were healthy and, 
if abnormality was detected, to ensure 
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prompt and adequate treatment by a 
qualified veterinarian. Before imple-
mentation, this protocol was reviewed 
by the Pfizer Ethical Review Board to 
ensure humane endpoints and suffi-
cient veterinary oversight. The feedlot 
was reviewed separately by the Pfizer 
Third Party Animal Welfare Risk 
Assessment team before experiment 
initiation.
Metaphylactic and Treatment 
Therapy
According to their treatment as-
signment, each heifer in a pen was 
injected on d 0 with either tulathro-
mycin (113.5 mg/45.4 kg of BW; T01; 
s.c.) or tilmicosin phosphate (450 
mg/45.4 kg of BW; T02; s.c.) based 
on individual animal BW at the time 
of processing. Dose was rounded up to 
the nearest 0.5 mL.
Heifers were observed daily for gen-
eral health by pen riders masked to 
treatment assignment on d 0 to 208. 
A system of clinical appearance score 
(CAS; scale of 1 to 5; Table 2) was 
defined (Johnson et al., 2008). A heif-
er was clinically diagnosed with BRD 
if scored a CAS ≤2 and had a rectal 
temperature ≥40.0°C or had a CAS 
≥3 (regardless of rectal temperature). 
Such heifers were pulled for treat-
ment. If an animal displayed CAS = 
5, the animal was humanely eutha-
nized. During the PMI period, cattle 
were observed daily for animal welfare 
concerns, but no CAS were assigned. 
After the PMI period, masked pen 
riders would record animals display-
ing clinical signs of BRD (i.e., dys-
pnea, tachypnea, depression, nasal or 
ocular discharge, inappetance, fever) 
and provide this information to the 
hospital crew. The unmasked hospital 
crew would pull the calves and treat 
according to the PMI/PTI treat-
ment protocol. Calves were scored by 
exception—only those demonstrating 
abnormal clinical signs (BRD or other 
medical conditions) were recorded.
A PMI was observed following ini-
tial metaphylactic treatments during 
which daily health observations were 
made, but no CAS were assigned nor 
treatments given. The PMI was 14 
d for T01 and 3 d for T02 (Table 1). 
The PMI was established based on 
the pharmacokinetic profile of each 
therapy tested or product labels, as 
well as use of common feedlot thera-
peutic programs (Hibbard et al., 2004; 
Kilgore et al., 2005; Robb et al., 2007; 
Step et al., 2007; Van Donkersgoed 
et al., 2008; Cox et al., 2010). Follow-
ing the PMI, heifers diagnosed with 
clinical BRD, as described above, 
received SFLT (Table 1) as follows. 
Treatment group T01 heifers received 
CCFA as a single s.c. injection in the 
ear at the dose of 6.6 mg of ceftiofur 
equivalents/kg of BW followed by a 
7-d PTI, during which daily clinical 
observations were made but no treat-
ments were given. The 7-d PTI for 
CCFA was established based on the 
product pharmacokinetic profile as 
well as previous reports (Hibbard et 
al., 2004; Washburn et al., 2009). Fol-
lowing the CCFA PTI, heifers display-
ing BRD were treated subsequently 
with a secondary SFLT consisting of 
florfenicol (Nuflor Injectable Solution; 
300 mg/mL; Intervet Schering-Plough 
Inc.) as a single s.c. injection into the 
neck at a dose rate of 40 mg/kg of 
BW. Following florfenicol treatment, 
a 3-d PTI was followed during which 
daily observations were made but no 
treatments were given (FDA, 2012b). 
Heifers that subsequently displayed 
BRD received a tertiary SFLT con-
sisting of an injection of oxytetracy-
cline (Liquamycin LA-200 Injectable 
Solution; Pfizer Animal Health) at a 
dose rate of 19.8 mg of oxytetracy-
cline/kg of BW.
Treatment group T02 heifers re-
ceived enrofloxacin dosed once as a 
s.c. injection of 12.5 mg/kg of BW as 
per label followed by a 4-d PTI during 
which daily observations were made 
but no treatments were given. The 
PTI for this product was established 
based on a previous report (Robb 
et al., 2007) in which enrofloxacin 
provided control of BRD (CAS ≥2) 
through d 4, after treatment. Follow-
ing the enrofloxacin PTI, heifers were 
treated for BRD consistent with the 
secondary and tertiary SFLT used for 
T01 heifers.Ta
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Chronically ill calves were defined 
as those that required additional 
therapy for BRD after the last (i.e., 
tertiary) SFLT treatment had been 
administered. Chronically ill animals 
were removed from the experiment. 
Removals were documented, and 
animals were removed from the home 
pen, weighed, and placed in pens with 
other culled or sick animals receiving 
the treatment of their home pen.
Diets, Feeding,  
and Management
Diets were formulated to meet or 
exceed NRC (2000) requirements for 
growth. Primary commodities used 
were steam-flaked corn, chopped 
alfalfa hay, choice white grease 
(when applicable), cane molasses 
(when applicable), supplement pel-
let, and microingredients. Each pen 
was provided feed thrice daily using 
a single-axle truck equipped with a 
mixer–delivery box. All diets and 
water were provided to allow for ad 
libitum consumption. Feed amounts 
delivered to each pen were recorded 
manually by the feed-truck driver 
and electronically by feed-truck scale 
system, and the delivery amount was 
printed at time of feeding. Bunks were 
managed by a clean-bunk system so 
the amount of feed provided daily was 
adjusted so bunks contained little to 
no orts after 24 h. On occasion, when 
feed remained in the bunk before the 
first feeding [e.g., inclement weather 
(i.e., rain, snow) or at the discretion 
of the site manager], it was removed, 
weighed, and sampled for DM con-
tent. An adjustment of daily intake 
was made on a DM basis.
Heifers were adjusted to a 95% 
concentrate diet using a series of 
diets. Because of the staggered starts 
of paired pens between 18 Novem-
ber and 2 December 2009, feed was 
provided initially on an experimental-
day basis. During d 0 to 24, 2.3 kg of 
stress diet 1 (also containing 1 g of 
chlortetracycline per 45.4 kg of BW) 
was provided for each heifer during 
the first 5 consecutive days of each 
successive 6-d interval. The balance 
of feed was offered as diet 2. Diets 
were then changed twice subsequently 
during the second feeding on calendar 
days corresponding to an average of 
50 d on feed. Specifically, all heifers 
were changed to diet 3 on 5 Janu-
ary 2010 (d 35 to 49 on feed) and to 
diet 4 on 12 January 2009 (d 42 to 
56 on feed) whereupon they remained 
through the end of the experiment, 
except with a minor change cited in 
Table 3. Additionally, stress diet 2 
(Table 3) was provided to all heifers 
as the initial 1.4 kg/heifer of feed on 
February 4 to 6, March 9 to 11, and 
May 4 to 6, 2010. Commencing 28 d 
before slaughter, diet 4 was supple-
mented with ractopamine hydrochlo-
ride (Optaflexx 45 Type A Medicated 
Article; Elanco Animal Health) at a 
level sufficient to supply 200 mg of 
ractopamine hydrochloride/heifer per 
day. On the day before slaughter, heif-
ers were provided 80% of the previous 
5-d average daily feed intake (as-fed 
basis).
Monensin sodium (Rumensin 90 
Type A Medicated Article; Elanco 
Animal Health) was included in diets 
2, 3, and 4 at a concentration of 30, 
37, and 44.4 g/909 kg (DM), respec-
Table 2. Clinical appearance scores (CAS) 
CAS1 Clinical appearance score descriptors including but not limited to:
Not recorded No bovine respiratory disease (BRD) clinical signs; calf is healthy and Bright Alert Responsive when approached.
  
1 Calf looks ill until approached by pen rider or person on foot (calf brightens up and appears normal). If pen rider 
loses sight of calf, upon re-exam of the pen, he/she CANNOT readily locate and ID calf as ill. Mild depression; 
slower in movement but no signs of weakness; small amount of serous nasal discharge; slight ocular discharge. If 
pulled as a “1”—take rectal temperature.
2 Calf is obviously ill with BRD; the calf shows no change in appearance when approached by pen rider or person 
on foot (does not brighten up). If pen rider loses sight of calf, upon re-exam of pen, he/she CAN easily locate and 
ID calf as ill. Moderate depression; signs of weakness or “knuckling” and calf may be reluctant to stand or move 
about pen; some shallowness apparent in left flank; considerable serous nasal discharge or moderate amount of 
mucopurulent nasal discharge; dyspnea or respiratory rate is increased; cough or coughing episodes are present. 
Take rectal temperature.
3 Calf is severely ill with BRD; abnormal respiratory or depression present and the animal could have scored 2 on 
the previous examination but was likely missed as a pull. Severe depression; stumbling or moves with extreme 
prodding; obvious lack of fill in left flank signaling anorexia; head lowered or extended to facilitate breathing; may 
be open-mouthed breathing with considerable noise (expiratory grunts, moans); copious mucopurulent to purulent 
nasal discharge; cough or coughing episodes are present. Treat regardless of rectal temperature.
4 Calf is moribund but is ambulatory and can be removed from pen for treatment without physical assistance. 
Considerable loss of condition, gaunt, eyes sunken; unable to rise or stand; unable to take feed or water; near 
death. Therefore, treatment is recommended course. Treat regardless of rectal temperature.
5 Calf is moribund and near death—calf is not ambulatory and cannot be removed from pen for treatment without 
physical assistance (e.g., tail up). Treatment not recommended; consider euthanasia as best option.
1Clinical data were not recorded during the postmetaphylaxis interval (program 1 = 14 d; program 2 = 3 d).
Stegner et al.212
tively. Tylosin phosphate (Tylan 100 
Type A Medicated Article; Elanco 
Animal Health) was included in diets 
2, 3, and 4 at a rate sufficient to sup-
ply 90 mg of tylosin phosphate/heifer. 
Melengestrol acetate (MGA 200 Pre-
mix Type A Medicated Article; Pfizer 
Animal Health) was added to diet 4 
at a rate sufficient to supply 0.4 mg 
of melengestrol acetate/heifer. Ru-
mensin, Tylan, MGA, and Optaflexx 
were added to the feed truck using a 
flush-bowl system. In brief, Rumen-
sin, Tylan, MGA, and Optaflexx were 
weighed to the nearest 0.01 g before 
being placed in the flush bowl and 
mixed with water. This slurry was 
then discharged onto the feed truck. 
The flush bowl was rinsed with water 
and again discharged onto the truck 
(Table 3).
Diets were sampled daily, and 
composites of these daily samples 
were analyzed at SDK Laboratory 
(Hutchinson, KS) for DM, CP, NPN, 
crude fiber, fat (EE), Ca, P, K, and 
S (Table 3). Monensin sodium con-
tent was assayed using a sample from 
a weekly composite (Covance Labs, 
Greenfield, IN).
Heifers were observed daily for ab-
normal conditions (morbidity, mortal-
ity, and adverse reactions). Animals 
that either died or were euthanized 
(captive bolt followed by exsanguina-
tion) underwent necropsy by a quali-
fied veterinarian to ascertain cause of 
death. For heifers removed from the 
experiment, a qualified veterinarian 
diagnosed the cause for removal.
Pen BW of heifers were obtained on 
d 0 and 208; however, BW of individ-
ual heifers on d 71 were summed to 
obtain pen BW for analysis. Heifers 
were reimplanted on d 71. Feed intake 
was recorded daily. Feedlot perfor-
mance was calculated and statisti-
cally analyzed with dead animals and 
animals removed from the experi-
ment either included (“deads in”) or 
excluded (“deads out”). Dates were 
recorded for day on feed for heifers 
that died or were removed, and BW 
was recorded on the day a heifer was 
removed. The number of total days 
on feed was calculated as (day for 
heifers slaughtered + day for heif-
ers removed + day for heifers died)/
(number of heifers placed). Final BW 
for deads in was calculated as (total 
BW of slaughtered heifers + total 
BW of heifers removed)/(number of 
heifers placed). Total BW gain for 
deads in was calculated as (total BW 
of slaughtered heifers + total BW of 
heifers removed) − (total BW of heif-
ers placed). Average gain was calcu-
lated as (total gain)/(number heifers 
placed), and ADG for deads in was 
calculated as (total gain)/(total days 
on feed for slaughtered heifers + total 
days on feed for dead and removed 
heifers). Gain to feed was calculated 
as (total gain)/(total feed). The DMI 
was calculated as (total DMI)/(total 
days on feed for slaughtered heifers 
+ total days on feed for dead and 
removed heifers).
Slaughter Procedures
Heifers were slaughtered after an 
average of 208 d on feed at a commer-
cial processing facility in southwest 
Kansas on June 21 (blocks 1 through 
4) and 22 (blocks 5 through 8), 2010. 
Carcass measurements were obtained 
by trained personnel and included 
HCW, liver abscess scores (Elanco 
Products Company, 1974), and USDA 
Table 3. Ingredient and nutrient content (DM basis) of experimental diets 
Item
Diet
Stress 1 Stress 2 2 3 4 41
Flaked corn, % 61.20 72.20 62.60 72.00 84.90 86.50
Dairy alfalfa hay, % 20.10 4.90 26.00 16.20 5.00 5.10
Cane molasses, % 7.00 0.00 5.40 3.60 0.00 0.00
Grease, choice white, % 0.00 3.90 1.30 2.90 4.20 2.50
Finisher supplement,2 % 0.00 0.00 4.70 5.30 5.90 5.90
Starter supplement,3 % 11.70 19.00 0.00 0.00 0.00 0.00
Feed additive,4 % 0.00 0.00 0.00 0.00 0.00 0.00
DM, % 81.57 81.67 78.39 78.76 79.23 78.94
CP, % 12.95 12.63 14.08 13.34 12.55 12.54
NPN, % 0.70 1.14 2.09 2.34 2.58 2.59
Ether extract, % 3.11 7.58 4.02 5.89 7.54 6.17
Ca, % 0.59 0.45 0.89 0.80 0.66 0.67
P, % 0.29 0.31 0.30 0.30 0.31 0.31
S, % 0.21 0.10 0.21 0.17 0.11 0.11
1Diet 4 modified as indicated on 1 April 2009 because of ingredient costs.
2Contained at least 60% CP and no more than 44% NPN (DM basis).
3Contained at least 27% CP, no more than 6% NPN, and at least 20,111 g of chlortetracycline per tonne (DM basis).
4Supplied monensin in diets 2, 3, and 4 at 30, 37, and 44.4 g/909 kg (DM basis). Also supplied 90 mg of tylosin/heifer daily in rations 
2, 3, and 4; 0.4 mg of melengestrol acetate/heifer daily in diet 4; and 200 mg of ractopamine HCl/heifer daily 28 d before slaughter.
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QG and YG. Marbling scores, LM 
area, and 12th-rib backfat measure-
ments were also obtained using the 
Computer Vision System (Research 
Management Systems Inc., Ft. Col-
lins, CO). All slaughter procedures 
followed were similar to previous re-
ports (Mader and Lechtenberg, 2000).
Statistical Analyses
The primary variable was incidence 
of BRD, defined as the proportion of 
calves in each treatment group treat-
ed for clinical BRD, including BRD 
mortalities, which occurred before a 
heifer would have been treated for 
BRD. Secondary variables included 
BRD relapses (subsequent recurrences 
of BRD), BRD mortality, and BRD 
chronics. In addition, performance 
measurements included ADG, DMI, 
G:F, carcass measures, and total 
economic returns. Differences (or lack 
thereof) between treatments were 
based on clinical or biological rel-
evance, and, as established a priori, 
statistical differences tested at α 
≤0.10. Pen was the experimental unit 
for all variables. All analyses were 
conducted using SAS/STAT Software 
(Version 9.1.3, SAS Institute Inc., 
Cary, NC).
Incidence of BRD (yes or no); BRD 
mortality (death or survive); BRD 
relapse measured by additional treat-
ments for BRD, second, third, and 
higher (yes or no); and BRD chronic 
incidence (yes or no) were analyzed 
using a generalized linear mixed 
model (Proc GLIMMIX; SAS Insti-
tute Inc.). The model included fixed 
effect of treatment and the random ef-
fects of block and block by treatment 
interaction, which was the pen term.
Pen BW (average BW per animal 
per pen) and G:F (per pen; deads-
in ADG {[(final BW − initial BW)/
heifer placed]/days on feed}/(total 
feed offered − total orts)/[(number 
of animals at the end of the period 
× days in period) + (total days of 
dead animals)]) were analyzed using 
a repeated measures mixed model. 
The mixed model included the fixed 
effect of treatment, time point, and 
treatment by time point and the 
random effect of block and block by 
treatment, which was the pen term. 
Average daily gain estimates were 
calculated and tested using linear 
combinations of parameter estimates.
Dry matter intake (total DM con-
sumed divided by total animal days 
per pen) was analyzed using a repeat-
ed-measures mixed model. The mixed 
model included the fixed effect of 
treatment, time point, and treatment 
by time point and the random effect 
of block and block by treatment, 
which was the pen term. Average 
daily gain estimates were calculated 
and tested using linear combinations 
of parameter estimates.
Carcass characteristics were summa-
rized with frequency tables (categori-
cal variables) or descriptive statistics 
(continuous variables), means, SD, 
and ranges for each treatment. Es-
timates of least squares means and 
SE were back transformed to their 
observed scale. Categorical carcass 
measures were converted to a binary 
number and analyzed with a general-
ized mixed model (Proc GLIMMIX; 
SAS Institute Inc.).
RESULTS AND DISCUSSION
Incidence of BRD
In this experiment, tulathromy-
cin, administered as a metaphylactic 
therapy in program 1 in high-risk 
animals upon feedlot arrival, reduced 
(P = 0.001) the initial incidence of 
BRD when compared with program 
2, using tilmicosin phosphate (Table 
4). A negative control or nonmedi-
cated group of contemporary calves 
(with no antimicrobial metaphylaxis 
administered on arrival) was not 
included in the experimental de-
sign; therefore, morbidity baseline 
was not determined. These results 
are similar to what has been previ-
ously demonstrated in use of these 
classes of antibiotics with a PMI (Van 
Donkersgoed et al., 2008) and without 
a PMI (Kilgore et al., 2005, Robb et 
al., 2007). From d 0 to 70 (includ-
ing the PMI period in which no CAS 
were assigned), incidence rate of BRD 
among T01 heifers was significantly 
lower (10.3 vs. 26.0%) than the rate 
observed for T02 heifers. Sixty-five of 
620 T01 heifers versus 160 of 616 T02 
heifers required subsequent treatment 
for BRD from d 0 to 70. Additionally, 
the percentage of heifers requiring 
re-treatment was less (P < 0.001) for 
T01 versus T02 heifers (1.6 vs. 6.3%, 
Table 4), although the percentage 
of chronics (i.e., cattle that required 
additional therapy for BRD after the 
last SFLT had been administered 
or were extremely unthrifty or poor 
performers, as assessed by the investi-
gator) was not influenced (P > 0.10). 
Potentially, confounding of incidence 
of BRD during the PMI period could 
have occurred because of the planned 
absence of clinical observation and 
the differing PMI lengths when com-
paring tulathromycin versus tilmico-
sin phosphate. However, in high-risk 
cattle, Kilgore et al. (2005) reported 
incidence of BRD relapse at 3 d after 
metaphylaxis (without a PMI) of 32, 
6, and 10% for saline-, tulathromy-
cin-, and tilmicosin-treated high-risk 
animals, respectively. In the same 
experiment, incidence of BRD relapse 
at 14 d after metaphylaxis was 58, 
13, and 28% for saline-, tulathromy-
cin-, and tilmicosin-treated animals, 
respectively. Additionally, to institute 
a 3-d PMI on tulathromycin or a 14-d 
PMI on tilmicosin phosphate would 
likely have ended in the same result, 
particularly in consideration of the 
differences in length of the pharma-
cokinetic profile for each product [43 
h (tilmicosin; Lombardi et al., 2011) 
versus 360 h (tulathromycin; Cox et 
al., 2010)]. From d 71 to 208, rates 
of BRD, re-treatment, mortality, 
or chronics were similar (P > 0.10; 
Table 4), whereas feedlot performance 
characteristics were improved for T01 
animals (P < 0.10; Table 5).
Evaluation of BRD-related charac-
teristics over the entire feedlot period 
(d 0 to 208) reflected what was seen 
during the initial 71 d. The early 
advantages persisted, resulting in the 
T01 heifers displaying lower incidence 
of BRD (P < 0.001) and re-treatment 
(P < 0.001) over the entire period in 
the feedlot (Table 4). A meta-analysis 
(Snowder et al., 2006) reported that 
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the greatest incidence of BRD oc-
curred within the first 80 d on feed 
with conflicting outcomes with regard 
to overall profitability. Wellman and 
O’Connor (2007) conducted a meta-
analysis using combined data from 
randomized clinical trials reporting 
treatment with tulathromycin, flor-
fenicol, or tilmicosin, reporting that 
tulathromycin was associated with an 
approximately 50% reduction in the 
risk of re-treatment for bovine respira-
tory disease compared with treatment 
with tilmicosin. This initial efficacy 
averts later clinical disease, which 
reduces production costs (Schunicht 
et al., 2007; Booker et al., 2007) and 
improves animal well-being.
Cox et al. (2010) demonstrated that 
tulathromycin is rapidly absorbed into 
pulmonary epithelial lining fluid, ex-
ceeding 1,000 ng/mL within 3 h. Tu-
lathromycin attained concentrations 
of more than 500 times plasma levels 
and maintained elevated concentra-
tions of 10,600 ng/mL in pulmonary 
epithelial lining fluid through 360 
h (Cox et al., 2010). The frequency 
of heifers ever treated for BRD is 
a noteworthy point. The respective 
numbers of heifers in the T01 versus 
T02 treatments, respectively, were as 
follows: treated once = 79 versus 167; 
treated ≥2 times = 11 versus 34, and 
treated 3 times = 6 versus 9. These 
observations demonstrate that further 
incidence of BRD (re-treatments post-
metaphylaxis) can be mitigated with 
the appropriate treatment program 
and further emphasize the importance 
of the metaphylactic portion of a 
therapeutic program. The results for 
treatment of BRD are also consistent 
with what has been reported previ-
ously. Lombardi et al. (2011) reported 
that tilmicosin maintains plasma 
concentrations above 90% minimum 
inhibitory concentration through 41 
and 43 h for light and heavy BW 
animals, respectively. Conversely, Cox 
et al. (2010) reported that tulathro-
mycin maintains bactericidal activity 
in pulmonary tissues through 360 
h postadministration in light-BW 
animals. These pharmacokinetic dif-
ferences set the stage for the number 
of BRD re-treatments observed in this 
experiment.
The pharmacokinetic profile of 
CCFA (Washburn et al., 2009) and 
actual feedlot use (Hibbard et al., 
2004; Step et al., 2007) have demon-
strated the benefit of using this anti-
biotic with a 7-d PTI for treatment 
of BRD in high-risk animals. The 
bactericidal profile of enrofloxacin 
is much shorter than that for CCFA 
(Robb et al., 2007; FDA, 2012a) and 
as the data in Table 4 illustrates, less 
efficacious. Early protection with a 
more effective therapeutic program 
improves animal well-being for a 
greater proportion of cattle in an 
environment where otherwise compa-
rable, similarly stressed cattle, given 
a less effective therapeutic program, 
experience a much greater initial 
incidence of BRD and are then predis-
posed to BRD recurrence (Snowder 
et al., 2006; Booker et al., 2007; S. E. 
Ives, 2012, Cactus Feeders, Amarillo, 
TX, personal communication).
Greater metaphylactic failure, 
greater relapse rates, or both result 
in greater resources needed to man-
age BRD before those affected cattle 
transition fully to the feedlot environ-
ment (McNeill et al., 1996; Snowder 
et al., 2006; Nickell and White, 2010). 
Overall mortality in this experiment 
was consistent with that reported for 
feeder cattle in a survey conducted 
between 2000 and 2008 (Cernicchiaro 
et al., 2012) where cumulative mor-
tality was 1.3%. In this experiment, 
BRD mortalities were similar across 
treatments (Table 4). Of the BRD 
mortalities occurring from d 0 to 70, 
only 5 occurred during the PMI (T01 
= 3 vs. T02 = 2). As subsequent 
courses of SFLT were needed, one T01 
heifer died, whereas 7 T02-treated 
heifers died. Overall, the therapeutic 
programs used under the conditions of 
this experiment were effective in mini-
mizing mortalities due to BRD (less 
than 2% for T02 and less than 1% for 
T01); however, there was insufficient 
evidence to conclude rates of mortali-
ty differed between these 2 treatments 
(P > 0.10).
Feedlot Performance
Initial BW and DMI were similar (P 
> 0.10) among treatments during the 
first 70 d of the trial (Table 5). On a 
Table 4. Effects of therapeutic programs on bovine respiratory disease (BRD) of feedlot heifers 
BRD item, %1
d 0 to 70 d 71 to 208 d 0 to 208
Treatment2
P-value
Treatment2
P-value
Treatment2
P-value
T01  
(n = 8)
T02  
(n = 8)
T01  
(n = 8)
T02  
(n = 8)
T01  
(n = 8)
T02  
(n = 8)
Incidence 10.3 26.0 <0.001  2.7 1.6 0.293  12.8 27.7 <0.001
Mortality 0.6 1.4 0.255  0.0 0.1 0.170  0.6 1.7 0.173
Retreatment 1.6 6.3 <0.001  0.0 0.0 0.351  2.0 6.4 0.006
Chronics 0.3 1.0 0.178  0.0 0.0 0.351  0.5 1.0 0.433
1Back transformed least squares means.
2T01 = metaphylactic tulathromycin + ceftiofur crystalline free acid [after 14-d treatment moratorium (PMI)]; T02 = metaphylactic 
tilmicosin + enrofloxacin (after 3-d PMI).
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deads-in basis, ADG was significantly 
greater in T01 versus T02 heifers 
(1.72 vs. 1.55; P = 0.021). However, 
on a deads-out basis ADG was similar 
between treatments (1.77 vs. 1.69, 
T01 vs. T02; P > 0.10). Consistent 
with these observations, BW for both 
treatments did not differ (P > 0.10) 
at either d 71 or at the end of the 
feeding period (Table 5). These data 
are similar to earlier reports (Booker 
et al., 2007; Van Donkersgoed et al., 
2008) and further substantiate the 
observed reduction in BRD during the 
first 70 d on feed. Average daily DMI 
overall was similar (P > 0.10; Table 
5) between treatments.
Gain to feed of T01 heifers from d 0 
to 70 [(0.283 vs. 0.268, T01 vs. T02, 
respectively; P = 0.099) and (0.274 
vs. 0.245, T01 vs. T02, respectively; P 
= 0.004)] was higher on a deads-out 
and deads-in basis, respectively (Table 
5). From d 71 to 208, G:F was similar 
(P > 0.10) among treatments, but 
when expressed over the entire feeding 
period, T01 heifers were more effi-
cient [(0.180 vs. 0.176, T01 vs. T02, 
respectively; P = 0.062) and (0.175 
vs. 0.165, T01 vs. T02, respectively; P 
= 0.034)] on a deads-out and deads-in 
basis, respectively. These results were 
similar to some reports (Booker et al., 
2007; Robb et al., 2007) but differed 
from other reports (Perrett et al., 
2008; Van Donkersgoed et al., 2008).
Differences in G:F on a deads-in 
versus a deads-out basis reflect the 
reduced total BW gain due to loss 
of dead animals and the feed they 
consumed. Expression of performance 
on a deads-out basis is more indica-
tive of actual cattle productivity and 
profitability. Gain to feed is generally 
higher on a deads-out basis because 
this estimate accounts for lost initial 
BW of dead calves and the feed that 
they consumed up until the time of 
death (Booker et al., 2007).
As with the measures of BRD, the 
decided G:F advantages gained during 
the initial period persisted throughout 
the entire experiment period and were 
realized at slaughter in terms of over-
all profitability. After acclimating to 
the feedlot environment (i.e., on and 
after d 71), heifers in both treatments 
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performed similarly in this experi-
ment. These observations demonstrate 
that any therapeutic program that 
reduces incidence of BRD early in 
the feeding period may result in an 
economic advantage across the entire 
feedlot period (Snowder et al., 2006; 
Booker et al., 2007).
Carcass Measures
Carcass measurements are summa-
rized in Table 6. Data were collected 
following processing by standard 
practices, similar to previous reports 
(Mader and Lechtenberg, 2000), in 
a commercial processing plant in 
southwest Kansas. Carcass traits 
were unremarkable, within industry 
standards, and did not differ because 
of treatment group (P > 0.10; Table 
6), which is consistent with previous 
reports (Schunicht et al., 2007).
Profitability Analysis
Overall costs and profitability were 
analyzed because of their importance 
in commercial production. The data 
are presented in Table 7 with the 
input assumptions cited as footnotes 
in that table. It is noteworthy that 
on average, the treatment medicine 
costs associated with each program 1 
(T01) heifer was less than a third that 
of each program 2 (T02) heifer. This 
outcome can be attributed to both 
the lower rates of BRD and reduced 
need for re-treatment among program 
1 (T01) heifers. Nickell and White 
(2010) estimated that BRD morbid-
ity rates need to be at least 25% for 
a metaphylaxis program to be cost 
effective, if overall treatment costs are 
$92.00/animal (McNeill et al., 1996). 
In this experiment, morbidity rates 
among T02 animals were 26%, follow-
ing the 3-d PMI. Because T01 heifers 
also had improved G:F over the entire 
experiment, their cost of gain was less 
when expressed on a deads-in basis 
($2.07 vs. $2.14 per kg of BW gain;  
P = 0.086), which is the more rel-
evant cost-of-production measurement 
as discussed earlier. Cost of gain did 
not differ on a deads-out basis, a vari-
able that puts a greater discount on 
the treatment group T02 heifers be-
cause of the greater incidence of BRD 
within this treatment group. Collec-
tively, there was a distinct profitabil-
ity advantage gained with program 1 
(P = 0.094), although this measure 
exhibited noteworthy variability (Ta-
ble 7). A model was developed using 
data reported from 5 earlier compara-
tive studies (Poulsen Nautrup et al., 
2011) that predicted overall benefits 
similar to those observed empirically 
with program 1 in this experiment. 
Results have varied in other studies 
with cattle at moderate risk for devel-
oping BRD (Van Donkersgoed et al., 
2008), which varied from the high-risk 
cattle used in the current experiment. 
There appear to be numerous and jus-
tifiable advantages of using a thera-
peutic program in calves at high-risk 
for BRD, and under the conditions of 
this experiment, program 1 resulted 
in an efficacious, cost-effective choice 
for stressed, incoming feedlot cattle at 
high risk for developing BRD.
In this experiment, use of therapeu-
tic program 1 [metaphylactic tulathro-
mycin plus as-needed SFLT for BRD 
(CCFA following a 14-d PMI; T01)] 
resulted in improved initial BRD 
control in high-risk calves upon ar-
rival to the feed yard compared with 
therapeutic program 2 [metaphylactic 
tilmicosin phosphate plus as-needed 
SFLT for BRD (enrofloxacin following 
a 3-d PMI; T02)]. Calves in program 
1 responded with a positive effect on 
overall health, ADG, G:F, and profit-
ability versus program 2. Carcass and 
carcass quality traits of economic im-
portance were similar for both BRD 
programs.
IMPLICATIONS
In general, whether in production 
medicine or in controlled studies, 
antimicrobial therapeutic programs 
can be efficacious in reduction of 
morbidity, mortality, and costs as-
sociated with BRD, while improving 
animal well-being. Any antimicrobial 
that reduces initial clinical BRD will 
likely also reduce BRD recurrence and 
the need for subsequent treatments, 
which should translate to improved 
individual animal performance and 
profitability. Our working hypothesis 
was that despite more expensive up-
front costs, program 1 (metaphylactic 
tulathromycin plus CCFA, as needed) 
Table 6. Carcass traits of heifers given therapeutic programs1 
Carcass trait
Treatment2
SE P-value
T01  
(n = 8)
T02  
(n = 8)
HCW, kg 334.70 330.40 3.70 >0.10
Backfat thickness, cm 1.24 1.22 0.05 >0.10
LM area, cm2 83.50 82.84 0.97 >0.10
KPH,3 % 2.91 2.81 0.16 >0.10
Empty body fat, % 36.74 36.49 0.28 >0.10
Marbling score4 550.48 550.43 7.18 >0.10
Choice and Prime, % 68.90 69.90  >0.10
USDA YG 2.96 2.92 0.06 >0.10
USDA YG ≤3, % 89.80 89.10  >0.10
Cutability, % 49.89 50.01  >0.10
Liver abscesses, % 37.70 39.20  >0.10
1Back transformed least squares means.
2T01 = metaphylactic tulathromycin + ceftiofur crystalline free acid [after 14-d 
treatment moratorium (PMI)]; T02 = metaphylactic tilmicosin + enrofloxacin (after 3-d 
PMI).
3KPH expressed as a percentage of carcass BW.
4Small 0 = 500.
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would provide an overall economic 
benefit to the end user. The pharma-
cokinetic profile and efficacy of these 
classes of antibiotics removed the 
need for BRD treatment for 14 and 7 
d, respectively, as well as reduced the 
need for re-treatment. This resulted in 
reduced labor costs for pen riders as 
well as medicine costs, both of which 
are major contributors to overall prof-
itability (Snowder et al., 2006; Booker 
et al., 2007).
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6Cost/mL for re-treatment of BRD: Excede = $1.67, Baytril = $0.70 (5.7 mL/cwt), Nuflor = $0.55 (6 mL/cwt), LA-200 = $0.10 (4.5 mL/
cwt). cwt (hundredweight) = 45.36 kg.
7Calculated as deads-out feed multiplied by [1 + (total BRD removal days/total animal days)].
8Includes yardage at $0.05/d, insurance at $0.12/mo, and 4.5% interest on purchase cost ($90/cwt).
9Assumes $94/45.4 kg of BW for finished cattle and $47/45.4 kg of BW for removed cattle, less $1 BEEF checkoff.
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